Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||uveal melanoma||not applicable||Mivebresib||Phase I||Actionable||In a Phase I trial, Mivebresib (ABBV-075) treatment demonstrated safety and modest clinical activity in patients with uveal melanoma, resulting in stable disease as best response in 44% (4/9) of evaluable patients, patients achieved stable disease had lower cfDNA mutational load of pathogenic mutations (53.1 vs 893.9 median mutant molecules/mL plasma) compared to patients developed progressive disease (J Clin Oncol 37, no. 15_suppl; NCT02391480).||detail...|
|PubMed Id||Reference Title||Details|
|Cell-free DNA in uveal melanoma: Results from the first-in-human trial of mivebresib (ABBV-075).||Full reference...|